Opicapone - BIAL

Drug Profile

Opicapone - BIAL

Alternative Names: [14C]-BIA 9-1067; BIA-91067; Ongentys; ONO-2370

Latest Information Update: 16 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIAL
  • Developer BIAL; Neurocrine Biosciences; Ono Pharmaceutical
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Feb 2018 Neurocrine Biosciences announces intention to submit NDA to the US FDA for Parkinson's disease in first half of 2019
  • 08 Feb 2018 Phase-I clinical trials in Parkinson's disease (Adjunctive treatment) in USA (PO) (NCT03496870)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top